OBSV ObsEva SA

2.71
-0.02  -1%
Previous Close 2.73
Open 2.73
Price To Book 1.27
Market Cap 119,261,750
Shares 44,008,026
Volume 237,570
Short Ratio
Av. Daily Volume 154,838
Stock charts supplied by TradingView

NewsSee all news

  1. ObsEva Announces Third Quarter 2019 Financial Results

    – Reports Update on Three Women's Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET

  2. ObsEva Announces Third Quarter 2019 Financial Results

    – Reports Update on Three Women's Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET

  3. Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

       Company to Discontinue Current Nolasiban IVF Program   Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies

  4. ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

      Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  5. ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

      Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 4Q 2019.
OBE2109 - PRIMROSE 2
Uterine fibroids
Phase 2a Part B interim analysis due 4Q 2019.
OBE022 - PROLONG
Pre-term labor
Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3.
OBE001 - IMPLANT2
IVF
Phase 3 data due 2Q 2020.
OBE2109 - PRIMROSE 1
Uterine fibroids
Phase 2b presented June 25, 2019.
OBE2109
Endometriosis
Phase 3 trial did not meet primary endpoint - November 10, 2019.
Nolasiban (OBE001) - IMPLANT 4
Improving IVF outcomes
Phase 3 trial to be initiated 4Q 2019 or early 2020.
Nolasiban (OBE001) - IMPLANT 3
IVF
Phase 3 initiation announced May 9, 2019.
Linzagolix (OBE2109)- EDELWEISS 2
Endometriosis
Phase 3 initiation announced May 9, 2019.
Linzagolix (OBE2109) - EDELWEISS 3
Endometriosis

Latest News

  1. ObsEva Announces Third Quarter 2019 Financial Results

    – Reports Update on Three Women's Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET

  2. ObsEva Announces Third Quarter 2019 Financial Results

    – Reports Update on Three Women's Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the Phase 2 Program for OBE022 – – Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET

  3. Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

       Company to Discontinue Current Nolasiban IVF Program   Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies

  4. ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

      Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  5. ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

      Geneva, Switzerland and Boston, MA –November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  6. ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  7. ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – November 6, 2019 - ObsEva SA (NASDAQ:OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that

  8. ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019

      Geneva, Switzerland and Boston, MA –November 4, 2019 - ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  9. ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

      FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of

  10. ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

    Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while maintaining bone

  11. ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

    Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while maintaining bone

  12. ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

    Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ:OBSV), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  13. ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

    Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ:OBSV), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  14. ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

    Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  15. ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

    Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  16. ObsEva announces new composition of its Executive Committee

    Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  17. ObsEva announces new composition of its Executive Committee

    Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious

  18. ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

    Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva's novel

  19. ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

    Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva's novel

  20. ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – August 30, 2019 - ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions

  21. ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – August 30, 2019 - ObsEva SA (NASDAQ:OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions